SCHEMBL2823306

SCHEMBL2823306

NNC(=O)C1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21455543 0.97 HDAC8 (0.54)
Hydrochloric Acid SCHEMBL4434325 0.97 HDAC8 (0.48)
Hydrochloric Acid SCHEMBL21585662 0.97
SCHEMBL21441786 0.95 HDAC8 (0.58)
SCHEMBL26188318 0.95 HDAC8 (0.58)
SCHEMBL23458806 0.94 HDAC8 (0.56)
SCHEMBL923125 0.94
SCHEMBL14823812 0.92 HDAC8 (0.61)
SCHEMBL293980 0.92 HDAC8 (0.61)
SCHEMBL5520084 0.92 HDAC8 (0.61)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3802501-B1 COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XWPHARMA LTD (KY) 2024-02-28 EP claimed
US-11424006-B2 Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide PSOMAGEN, INC. (US) 2022-08-23 US claimed
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MACROGEN INC. (KR) 2021-05-06 US claimed
EP-3668494-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE Psomagen, Inc. (US) 2020-06-24 EP claimed
CN-111163761-A Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide 普梭梅根公司 2020-05-15 CN claimed
WO-2019036507-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE uBiome, Inc. (US) 2019-02-21 WO claimed
US-20190050525-A1 RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES PSOMAGEN, INC. 2019-02-14 US claimed
JP-3698699-B2 2005-09-21 JP claimed
US-20040106724-A1 Natural rubber produced from latex and composition comprising the same BRIDGESTONE CORPORATION (JP) 2004-06-03 US claimed
JP-2004514009-A 2004-05-13 JP claimed
EP-1332161-A2 DRYING PROCESSES FOR NATURAL RUBBER, STABILIZED NR COMPOSITIONS Bridgestone Corporation (JP) 2003-08-06 EP claimed
WO-2002038667-A2 NATURAL RUBBER PRODUCED FROM LATEX AND COMPOSITION COMPRISING THE SAME BRIDGESTONE CORPORATION (JP) 2002-05-16 WO claimed
US-12637430-B2 Interleukin-17 (IL-17) inhibitors HITGEN INC. (CN) 2026-05-26 US disclosed
EP-4177249-B1 IMMUNOMODULATOR HITGEN INC (CN) 2025-12-03 EP disclosed
EP-4638436-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-10-29 EP disclosed
US-12338243-B2 P2X7 modulators JANSSEN PHARMACEUTICA NV (BE) 2025-06-24 US disclosed
EP-0218689-A1 ANTHELMINTIC QUINOLINYL ACYLHYDRAZONES AND COMPOSITIONS. UPJOHN CO (US) 1987-04-22 EP disclosed
EP-0214158-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1987-03-18 EP disclosed
WO-1986005982-A2 ANTHELMINTIC QUINOLINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS UPJOHN CO (US) 1986-10-23 WO disclosed
WO-1986004582-A1 ANTHELMINTIC PYRIDINYL ACYLHYDRAZONES, METHOD OF USE AND COMPOSITIONS THE UPJOHN COMPANY (US) 1986-08-14 WO disclosed